Gimatecan
As of the edition of 20 October 2026, Gimatecan is a small molecule: in active development; acts on TOP1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2020
- Kind
- Small molecule
- Registered trials
- 12, 0 stopped early
- Disease areas
- Cancer; Hormones; Pregnancy and women's health; Urinary and reproductive; Blood and lymph; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TOP1 | DNA topoisomerase 1 | P11387 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 7 | 6 | 0 | 0 |
| Phase 2 | 5 | 2 | 0 | 0 |
| All trials | 12 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Sigma Tau | Lead sponsor of trials | 2002 to now |
| Novartis | Lead sponsor of trials | 2006 to now |
| Lee's Pharmaceutical | Lead sponsor of trials | 2019 to now |